- Blog
- News & Media
- Issues
- About The Biopharmaceutical Sector
- Access and Affordability
- Adherence
- Appropriate Use Of Medicines
- Counterfeit Drugs
- Disaster Response
- Drug Safety
- Environmental Issues
- Food And Drug Administration
- Importation
- Intellectual Property
- International
- Medical Advances
- Medicare
- Prescription Drug Abuse
- Prescription Drug User Fee Act
- Sales And Marketing
- Value of Medicines
- Research
- About
The Catalyst
Clinical Trials – Discovering and Sharing Knowledge
02/02/2013 09:03 AM
By Matt Bennett
Developing a new medicine to fight diseases such as cancer or diabetes can require 12-15 years of research and over $1 billion. As seen in Catalyst posts earlier this week, a foundational aspect of the research is scientifically rigorous, well-regulated clinical trials. Recently, critics such as Dr. Ben Goldacre have sought to cast doubt on [...]
Communications Breakdowns in the Scientific Community – And How to Fix Them
02/01/2013 05:06 PM
By Jenni Brewer
A colleague shared with me today an opinion piece in The Scientist that got me thinking about physicians and their hectic lives. The article delved into the communication breakdown that is occurring in the scientific community. Author David Rubenson cited several challenges, including staying up to date with the “deluge of articles coming from the [...]
Trade Groups Take Stand to Protect Drug Supply
01/31/2013 04:03 PM
By Mark Grayson
The National Conference of Pharmaceutical Organizations (NCPO) highlighted important issues to keep the supply of medicines safe in the United States. According to Lucinda Maine, Executive Vice President and CEO of the American Association of Colleges of Pharmacy, “ Pharmacists are taught that medication safety is their highest professional priority. The integrity of the distribution [...]
The Spotlight
Similar to other statements below, I greatly appreciate the contribution of the PhRMA Foundation towards my career with a Pre Doctoral Fellowship in Pharmacology/Toxicology. The PhRMA Foundation's generosity has been essential to the development of leaders who are passionate about their research. This fellowship will enable me to focus on my project investigating the pharmaco- and toxicogenomics of anticancer agents. Ultimately, I will strive to improve patient care through translational endeavors. Thank you so much for supporting us!
February 1 at 9:48pm
Subscribe to our Email Updates
Facebook/Twitter Lists
This video highlights some of the many accomplishments over the past year, thanks to the hard work and persistence of the 600,000+ researchers, scientists and others working in the biopharma industry. We're confident that 2013 holds even greater promise. Like if you share our optimism. Share if you...
likes: 38 | comments: 1
PhRMA just contributed $50,000 to the Rotary International Club's "The World's Biggest Commercial." That is enough vaccine to protect more than 83,000 children against the paralyzing disease. Will you help end polio? Add your own picture at http://thisclose.endpolio.org/en and join the fight. ...
likes: 54 | comments: 4
Look back at over a century of presidential inaugurations and major advancements in medicines. Like this if you're excited about what the next century could bring. http://www.youtube.com/watch?v=tR97j9HErBs&sns=em
likes: 46 | comments: 4
#MedsInDev address diseases that have not seen new therapies in 10 yrs, says #PhRMA Chairman & @Lillypad CEO: http://t.co/bwlgEx1Y
01.29.2013 // Retweets: 5
#PhRMA Chairman & @Lillypad CEO Lechleiter says U.S. innovators account for 80% of world’s #biotech R&D. Learn more: http://t.co/bwlgEx1Y
01.29.2013 // Retweets: 5
Why does #biopharma flourish in the U.S.? #PhRMA Chairman @Lillypad CEO Lechleiter explains in @Forbes: http://t.co/bwlgEx1Y
01.28.2013 // Retweets: 4
On the verge of a pharmaceutical #R&D renaissance? #PhRMA Chairman & @Lillypad CEO Lechleiter explains in @Forbes: http://t.co/bwlgEx1Y
01.28.2013 // Retweets: 3
Helpful resources from #PhRMA CEO Press Club speech today: speech http://t.co/0ka9tfiT Related blog post: http://t.co/mQAxoYSt
09.20.2012 // Retweets: 3










